Given the positive role of CD155 in tumor growth, in the present study we asked whether Adriamycin (Adr) treatment [20–22] could upregulate CD155 expression in breast cancer cells, and whether CD155 knockdown could affect Adr-induced breast cancer cell apoptosis. This evidence concerns the gene PVR and neoplasm.